I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Ovarian Cancer

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Oct 16 / Roche and Genentech
Clinical outcomes with trastuzumab emtansine (T-DM1) or ipatasertib plus paclitaxel for persistent/recurrent rare epithelial ovarian cancer: ENGOT-GYN2/GOG-3051/BOUQUET phase 2 biomarker-directed study
The BOUQUET international platform study (NCT04931342) is evaluating biomarker-directed regimens for rare eOCs. Here, we report results from two treatment arms: trastuzumab emtansine (T-DM1) in patients with ERBB2-amplified and/or -mutated tumours, and ipatasertib + paclitaxel in patients with PIK3CA/AKT1/PTEN-altered tumours.

Sign up or login to unlock the full suite of MEDICALLY features

Apr 9 / Roche and Genentech
Tumor Microenvironment (TME) biomarkers of TIGIT and PD-L1 immune checkpoint blockade in Cervical Cancer: An Exploratory Biomarker Analysis from SKYSCRAPER-04 (SKY04) Study
Immune checkpoint blockade (ICB) is a new treatment option for advanced cervical cancer. SKYSCRAPER-04 (NCT04300647) explored the clinical activity of Tiragolumab (T, anti-TIGIT) plus atezolizumab (A, anti-PD-L1) dual immune checkpoint blockade (T+A) in patients (pts) with PD-L1+ cervical cancer. The goal of this biomarker exploratory sub-study was to characterize the tumor microenvironment of cervical cancer and its association with ICB clinical activity and Tiragolumab clinical outcome.

Sign up or login to unlock the full suite of MEDICALLY features

Oct 23 / Roche and Genentech
First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase 2 biomarker-directed platform study: cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)
BOUQUET is a platform study of multiple treatments in biomarker-selected patients with rare epithelial ovarian cancer. First results from the cobimetinib and the atezolizumab + bevacizumab cohorts are reported.

Sign up or login to unlock the full suite of MEDICALLY features

Jun 3 / Roche
Roche Pathology Lab: Innovation in Personalised Healthcare
This talk introduced Roche Pathology Laboratory’s recent innovations in personalized healthcare, with focus on medical evidence related to PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody, VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, VENTANA CLDN18 (43-14A) Assay, VENTANA PD-L1 (SP263) Assay, and a glimpse into the pipeline. This content is intended for HCPs who have attended the symposium.

Sign up or login to unlock the full suite of MEDICALLY features

Apr 18 / Roche and Genentech
Ovarian Cancer Tumor Microenvironment and Atezolizumab Clinical Activity: IMagyn050 sub-study
The goal of this exploratory study: to evaluate the association of tumor features with atezolizumab clinical activity in front line ovarian cancer patients in the IMagyn050 study.

Sign up or login to unlock the full suite of MEDICALLY features

Independent content
Sep 19 / Springer Healthcare
ESMO 2021 Gynaecological cancer highlights
Days 1 and 2 at the ESMO Congress 2021 saw some potentially practice-changing data presented in the fields of cervical and ovarian cancer.

Ask a question or share feedback